320 related articles for article (PubMed ID: 32002567)
1. First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany.
Klüter S; Katayama S; Spindeldreier CK; Koerber SA; Major G; Alber M; Akbaba S; Debus J; Hörner-Rieber J
Strahlenther Onkol; 2020 Aug; 196(8):691-698. PubMed ID: 32002567
[TBL] [Abstract][Full Text] [Related]
2. First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.
Sahin B; Zoto Mustafayev T; Gungor G; Aydin G; Yapici B; Atalar B; Ozyar E
Cureus; 2019 Dec; 11(12):e6457. PubMed ID: 32025388
[TBL] [Abstract][Full Text] [Related]
3. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported Outcome Measurements on the Tolerance of Magnetic Resonance Imaging-guided Radiation Therapy.
Tetar S; Bruynzeel A; Bakker R; Jeulink M; Slotman BJ; Oei S; Haasbeek C; De Jong K; Senan S; Lagerwaard F
Cureus; 2018 Feb; 10(2):e2236. PubMed ID: 29719739
[TBL] [Abstract][Full Text] [Related]
5. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Tolerance of Magnetic Resonance-Guided Radiation Therapy.
Sayan M; Serbez I; Teymur B; Gur G; Zoto Mustafayev T; Gungor G; Atalar B; Ozyar E
Front Oncol; 2020; 10():1782. PubMed ID: 33072560
[TBL] [Abstract][Full Text] [Related]
7. Prospective feasibility analysis of a novel off-line approach for MR-guided radiotherapy.
Bostel T; Pfaffenberger A; Delorme S; Dreher C; Echner G; Haering P; Lang C; Splinter M; Laun F; Müller M; Jäkel O; Debus J; Huber PE; Sterzing F; Nicolay NH
Strahlenther Onkol; 2018 May; 194(5):425-434. PubMed ID: 29349601
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.
Mazzola R; Cuccia F; Figlia V; Rigo M; Nicosia L; Giaj-Levra N; Ricchetti F; Vitale C; Mantoan B; Di Paola G; De Simone A; Gurrera D; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Radiol Med; 2021 Jul; 126(7):989-997. PubMed ID: 33835309
[TBL] [Abstract][Full Text] [Related]
9. MRI-guided Radiotherapy (MRgRT) for Treatment of Oligometastases: Review of Clinical Applications and Challenges.
Chetty IJ; Doemer AJ; Dolan JL; Kim JP; Cunningham JM; Dragovic J; Feldman A; Walker EM; Elshaikh M; Adil K; Movsas B; Parikh PJ
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):950-967. PubMed ID: 35901978
[TBL] [Abstract][Full Text] [Related]
10. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
[TBL] [Abstract][Full Text] [Related]
11. Initial clinical experience with magnetic resonance-guided radiotherapy in pediatric patients: Lessons learned from a single institution with proton therapy.
Hall MD; Mittauer KE; Herrera R; Von Werne K; Kotecha R; Kalman NS; McCulloch J; Alvarez D; McAllister NC; Doty DG; Rzepczynski AE; Deere W; Gutierrez AN; Chuong MD
Front Oncol; 2022; 12():1037674. PubMed ID: 36713501
[TBL] [Abstract][Full Text] [Related]
12. Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia.
Slotman BJ; Clark MA; Özyar E; Kim M; Itami J; Tallet A; Debus J; Pfeffer R; Gentile P; Hama Y; Andratschke N; Riou O; Camilleri P; Belka C; Quivrin M; Kim B; Pedersen A; van Overeem Felter M; Kim YI; Kim JH; Fuss M; Valentini V
Radiat Oncol; 2022 Aug; 17(1):146. PubMed ID: 35996192
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance-guided radiotherapy feasibility in elderly cancer patients: proposal of the MASTER scoring system.
Boldrini L; Colloca GF; Villani E; Chiloiro G; Bellieni A; Manfrida S; Cellini F; Gambacorta MA; Valentini V
Tumori; 2021 Feb; 107(1):26-31. PubMed ID: 32410505
[TBL] [Abstract][Full Text] [Related]
15. Time-Driven Activity-Based Costing Comparison of CT-Guided Versus MR-Guided SBRT.
Parikh NR; Lee PP; Raman SS; Cao M; Lamb J; Tyran M; Chin W; Gilchrist T; Agazaryan N; Mittauer K; Steinberg ML; Raldow AC
JCO Oncol Pract; 2020 Nov; 16(11):e1378-e1385. PubMed ID: 32539652
[TBL] [Abstract][Full Text] [Related]
16. Real-time Magnetic Resonance-guided Liver Stereotactic Body Radiation Therapy: An Institutional Report Using a Magnetic Resonance-Linac System.
Feldman AM; Modh A; Glide-Hurst C; Chetty IJ; Movsas B
Cureus; 2019 Sep; 11(9):e5774. PubMed ID: 31723533
[TBL] [Abstract][Full Text] [Related]
17. Medical physics challenges in clinical MR-guided radiotherapy.
Kurz C; Buizza G; Landry G; Kamp F; Rabe M; Paganelli C; Baroni G; Reiner M; Keall PJ; van den Berg CAT; Riboldi M
Radiat Oncol; 2020 May; 15(1):93. PubMed ID: 32370788
[TBL] [Abstract][Full Text] [Related]
18. MRI-guided stereotactic radiation therapy for hepatocellular carcinoma: a feasible and safe innovative treatment approach.
Boldrini L; Romano A; Mariani S; Cusumano D; Catucci F; Placidi L; Mattiucci GC; Chiloiro G; Cellini F; Gambacorta MA; Indovina L; Valentini V
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2057-2068. PubMed ID: 33398447
[TBL] [Abstract][Full Text] [Related]
19. Clinical application of MR-Linac in tumor radiotherapy: a systematic review.
Liu X; Li Z; Yin Y
Radiat Oncol; 2023 Mar; 18(1):52. PubMed ID: 36918884
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes.
Mazzola R; Figlia V; Rigo M; Cuccia F; Ricchetti F; Giaj-Levra N; Nicosia L; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2379-2397. PubMed ID: 32372146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
